<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051463</url>
  </required_header>
  <id_info>
    <org_study_id>2019-007</org_study_id>
    <nct_id>NCT04051463</nct_id>
  </id_info>
  <brief_title>Rhopressa for Corneal Edema Associated With Fuchs Dystrophy</brief_title>
  <official_title>Prospective Randomized Study to Determine Whether Use of Rhopressaâ„¢ Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to determine whether use of Rhopressa improves the ability of corneal&#xD;
      endothelial cells to maintain appropriate corneal hydration in patients with Fuchs&#xD;
      endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a&#xD;
      corneal transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The active drug and placebo will be provided in 2.5 ml bottles identical, in appearance. Only the designated dosing coordinator is unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Central Corneal Thickness</measure>
    <time_frame>1 month</time_frame>
    <description>Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Corrected Distance Visual Acuity (CDVA)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Fuchs Endothelial Dystrophy</condition>
  <arm_group>
    <arm_group_label>Netarsudil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil Ophthalmic Solution</intervention_name>
    <description>Netarsudil eye drops instilled once daily</description>
    <arm_group_label>Netarsudil</arm_group_label>
    <other_name>Rhopressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo eye drops instilled once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Rhopressa vehicle without active ingredient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam&#xD;
             and/or corneal tomography.&#xD;
&#xD;
          -  Patient is able and willing to administer eye drops.&#xD;
&#xD;
          -  Patient is able to comprehend and has signed the Informed Consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.&#xD;
&#xD;
          -  Known sensitivity to any of the ingredients in the study medications.&#xD;
&#xD;
          -  Abnormal eyelid function.&#xD;
&#xD;
          -  History of herpetic keratitis.&#xD;
&#xD;
          -  History of non-compliance with using prescribed medication.&#xD;
&#xD;
          -  Current or planned pregnancy within the study duration.&#xD;
&#xD;
          -  Concurrent involvement or participation in another randomized clinical trial within 30&#xD;
             days prior to enrollment in this study.&#xD;
&#xD;
          -  Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation&#xD;
             which in the investigator's opinion may put the patient at significant risk, confound&#xD;
             the study results, or interfere significantly with the patient's participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Price MO, Price FW Jr. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy. Am J Ophthalmol. 2021 Jul;227:100-105. doi: 10.1016/j.ajo.2021.03.006. Epub 2021 Mar 15.</citation>
    <PMID>33737034</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <results_first_submitted>August 27, 2021</results_first_submitted>
  <results_first_submitted_qc>August 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2021</results_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04051463/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Netarsudil</title>
          <description>A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.&#xD;
Netarsudil Ophthalmic Solution: Netarsudil eye drops instilled once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.&#xD;
Placebo: Placebo eye drops instilled once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Netarsudil</title>
          <description>A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.&#xD;
Netarsudil Ophthalmic Solution: Netarsudil eye drops instilled once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.&#xD;
Placebo: Placebo eye drops instilled once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="5"/>
                    <measurement group_id="B2" value="69" spread="7"/>
                    <measurement group_id="B3" value="68" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Central Corneal Thickness</title>
        <description>Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Netarsudil</title>
            <description>A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.&#xD;
Netarsudil Ophthalmic Solution: Netarsudil eye drops instilled once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.&#xD;
Placebo: Placebo eye drops instilled once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Corneal Thickness</title>
          <description>Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23" lower_limit="-32" upper_limit="-13"/>
                    <measurement group_id="O2" value="-2" lower_limit="-9" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Corrected Distance Visual Acuity (CDVA)</title>
        <description>Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Netarsudil</title>
            <description>A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.&#xD;
Netarsudil Ophthalmic Solution: Netarsudil eye drops instilled once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.&#xD;
Placebo: Placebo eye drops instilled once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Corrected Distance Visual Acuity (CDVA)</title>
          <description>Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline)</description>
          <units>lines on the eye chart</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.8" upper_limit="3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-0.7" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Netarsudil</title>
          <description>A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.&#xD;
Netarsudil Ophthalmic Solution: Netarsudil eye drops instilled once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.&#xD;
Placebo: Placebo eye drops instilled once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>conjunctival hyperemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>ocular irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>glare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>lacrimation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marianne Price</name_or_title>
      <organization>Cornea Research Foundation of America</organization>
      <phone>317-814-2990</phone>
      <email>mprice@cornea.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

